Tyrosine kinase inhibitors suppress the growth of non-Hodgkin B lymphomas

Journal of Pharmacology and Experimental Therapeutics

Volumn 303, Issue 1, 2002, Pages 163-171

  Ben Bassat, Hannah ^a   Hartzstark, Zipora ^b   Levitzki, Rubina ^a   Y klein, Benjamin ^b   Shlomai, Zipora ^a   Gazit, Aviv ^b   Levitzki, Alexander ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AG 542; AG 588; AG 589; AG 596; AGL 2592; PROTEIN TYROSINE KINASE INHIBITOR; TYRPHOSTIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RECURRENCE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG POTENCY; DRUG SENSITIVITY; DRUG STRUCTURE; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR GROWTH;

ANTIBODIES, MONOCLONAL; APOPTOSIS; CATECHOLS; CELL DIVISION; ENZYME INHIBITORS; FEMALE; HUMANS; KINETICS; LYMPHOMA, NON-HODGKIN; NITRILES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-BCL-2; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0036784513     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.036723     Document Type: Article

References (37)

1. Adams JM and Cory S (1998) The Bcl-2 protein family: arbiters of cell survival. Science (Wash DC) 281:1322-1326.
2. Ben-Bassat HPA, Shlomai Z, Kohn G, Hadar R, Rabinowitz R, Leizerowitz R, Matutes E, Buchier V, Brok-Simoni F, Okon E, et al. (1992) Farage, a novel early B cell lymphoma cell line with trisomy 11. Leuk Lymphoma 6:513-521.
3. Ben-Bassat H, Weksler-Zangen S, Shlomai Z, and Prokocimer M (1987) Interaction of soybean agglutinin with human leukemia-lymphoma lines at various stages of differentiation. Leuk Res 11:589-595.
4. Bosly A, Haioun C, Gisselbrecht C, Reyes F, and Coiffier B (2001) High-dose treatment with autologous stem cell transplantation versus sequential chemotherapy: the GELA experience. Eur J Haematol Suppl 64:3-7.
5. Bowman T, Garcia R, Turkson J, and Jove R (2000) STATs in oncogenesis. Oncogene 19:2474-2488.
6. Bowman T and Jove R (1999) STAT Proteins and Cancer. Cancer Control 6:615-619.
7. Canellos GP (1998) Treatment of relapsed Hodgkin's disease: strategies and prognostic factors. Ann Oncol 9:S91-S96.
8. Carlo-Stella C, Regazzi E, Sammarelli G, Colla S, Garau D, Gazit A, Savoldo B, Cilloni D, Tabilio A, Levitzki A, et al. (1999) Effects of the tyrosine kinase inhibitor AG957 and an Anti-Fas receptor antibody on CD34(+) chronic myelogenous leukemia progenitor cells. Blood 93:3973-3982.
9. Catlett-Falcone R, Dalton WS, and Jove R (1999a) STAT proteins as novel targets for cancer therapy: signal transducer and activator of transcription. Curr Opin Oncol 11:490-496.
10. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna JL, Nunez G, et al. (1999b) Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10:105-115.
11. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, et al. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244.
12. Coiffier B, Gisselbrecht C, Vose JM, Tilly H, Herbrecht R, Bosly A, and Armitage JO (1991) Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs. J Clin Oncol 9:211-219.
13. Davis TA, Grillo-Lopez AJ, White CA, McLaughlin P, Czuczman MS, Link BK, Maloney DG, Weaver RL, Rosenberg J, and Levy R (2000a) Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of Re-treatment [In Process Citation]. J Clin Oncol 18:3135-3143.
14. Davis TA, Maloney DG, Grillo-Lopez AJ, White CA, Williams ME, Weiner GJ, Dowden S, and Levy R (2000b) Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-α-2a [In Process Citation]. Clin Cancer Res 6:2644-2652.
15. Davis TA, White CA, Grillo-Lopez AJ, Velasquez WS, Link B, Maloney DG, Dillman RO, Williams ME, Mohrbacher A, Weaver R, et al. (1999) Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin Oncol 17:1851-1857.
16. Druker BJ and Lydon NB (2000) Lessons learned from the development of an ab1 tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 105:3-7.
17. Dumontet C, Thieblemont C, Espinouse D, Bouafia F, Hequet O, Salles G, and Coiffier B (2000) A prospective study of intensive induction therapy with high-dose consolidation in patients with aggressive non-Hodgkin's lymphoma and two or three adverse prognostic factors. Leukemia 14:2159-2165.
18. Haldar S, Basu A, and Croce CM (1997) Bcl2 is the guardian of microtubule integrity. Cancer Res 57:229-233.
19. Haldar S, Jena N, and Croce CM (1995) Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA 92:4507-4511.
20. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, and Vardiman J (2000) Lymphoma classification-from controversy to consensus: the REAL and WHO classification of lymphoid neoplasms. Ann Oncol 11:3-10.
21. Karni R and Levitzki A (2000) pp60(cSrc) is a caspase-3 substrate and is essential for the transformed phenotype of A431 cells. Mol Cell Biol Res Commun 3:98-104.
22. Levitzki A (1992) Tyrphostins: tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction. FASEB J 6:3275-3282.
23. Levitzki A (1999) Protein tyrosine kinase inhibitors as novel therapeutic agents. Pharmacol Ther 82:231-239.
24. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, et al. (1997) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed lowgrade non-Hodgkin's lymphoma. Blood 90:2188-2195.
25. Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, Lapidot Z, Leeder JS, Freedman M, Cohen A, Gazit A, et al. (1996) Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature (Lond) 379:645-648.
26. Nagane M, Levitzki A, Gazit A, Cavenee WK, and Huang HJ (1998) Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc Natl Acad Sci USA 95:5724-5729.
27. Niu G, Heller R, Catlett-Falcone R, Coppola D, Jaroszeski M, Dalton W, Jove R, and Yu H (1999) Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res 59:5059-5063.
28. Pezzella F, Tse AG, Cordell JL, Pulford KA, Gatter KC, and Mason DY (1990) Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation. Am J Pathol 137:225-232.
29. Piris MA, Pezzella F, Martinez-Montero JC, Orradre JL, Villuendas R, Sanchez-Beato M, Cuena R, Cruz MA, Martinez B, Pezella F, et al. (1994) p53 and bcl-2 expression in high-grade B-cell lymphomas: correlation with survival time [published erratum appears in Br J Cancer (1994) 69:978]. Br J Cancer 69:337-341.
30. Potter M (1992) Pathogenetic mechanisms in B-cell non-Hodgkin's lymphomas in humans. Cancer Res 52:5522s-5528s.
31. Reed JC (1998) Bcl-2 family proteins. Oncogene 17:3225-3236.
32. Reed JC, Tanaka S, and Cuddy M (1992) Cell cycle analysis of p26-BCL-2 protein levels in proliferating lymphoma and leukemia cell lines. Cancer Res 52:2802-2805.
33. Salzman DE, Briggs AD, and Vaughan WP (1997) Bone marrow transplantation for non-Hodgkin's lymphoma: a review. Am J Med Sci 313:228-235.
34. Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, Taidi B, Rajapaksa R, Caspar CB, Okada CY, et al. (2002) Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 99:1517-1526.
35. Weber-Nordt RM, Egen C, Wehinger J, Ludwig W, Gouilleux-Gruart V, Mertelsmann R, and Finke J (1996) Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. Blood 88:809-816.
36. Ye BH (2000) BCL-6 in the pathogenesis of non-Hodgkin's lymphoma. Cancer Invest 18:356-365.
37. Zutter M, Hockenbery D, Silverman GA, and Korsmeyer SJ (1991) Immunolocalization of the Bcl-2 protein within hematopoietic neoplasms. Blood 78:1062-1068.